Safety, pharmacokinetic, and pharmacodynamics of erdafitinib, a pan-fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitor, in patients with advanced or refractory solid tumors
2017 ◽
Vol 36
(3)
◽
pp. 424-434
◽
2009 ◽
Vol 15
(2)
◽
pp. 520-531
◽
1990 ◽
Vol 265
(27)
◽
pp. 16455-16463
◽